PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Not Recruiting

Trial ID: NCT01515787,9,56


The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.

Official Title

A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)

Stanford Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Heather Wakelee
Heather Wakelee

Professor of Medicine (Oncology)


Registration Inclusion Criteria:

   1. Age ≥ 18 years at diagnosis

   2. Diagnosis of rectal adenocarcinoma

   3. Radiologically measurable or clinically evaluable disease as defined in the protocol

   4. ECOG Performance Status (PS): 0, 1 or 2

   5. For this patient, the standard treatment recommendation in the absence of a clinical
   trial would be combined modality neoadjuvant chemoradiation followed by curative
   intent surgical resection

   6. Candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy
   according to the primary surgeon

   7. Primary surgeon is credentialed or is willing to be credentialed in Total Mesorectal
   Excision (TME), which entails submission of photos of a single TME specimen either
   before enrolling the first patient or by using the surgeon's 1st accrued case.

   8. Clinical Stage: T2N1, T3N0, T3N1.

      - N2 disease is to be estimated as four or more lymph nodes that are ≥ 10 mm.

      - Clinical staging should be estimated based on the combination of the following
      assessments: physical exam by the primary surgeon, CT or PET/CT scan of the
      chest/abdomen/pelvis and either a pelvic MRI or an ultrasound (ERUS). If a pelvic
      MRI is peformed, it is acceptable to perform CT of the chest/abdomen, ommitting
      CT imaging of the pelvis.

   9. The following laboratory values obtained ≤ 28 days prior to registration:

      - Absolute neutrophil count (ANC) ≥ 1500/mm^3

      - Platelet count ≥ 100,000/mm^3

      - Hemoglobin > 8.0 g/dL

      - Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

      - SGOT (AST) ≤ 3 x ULN

      - SGPT (ALT) ≤ 3 x ULN

      - Creatinine ≤1.5 x ULN

10. Negative pregnancy test done ≤ 7 days prior to registration, for women of childbearing
   potential only

11. Patient of child-bearing potential is willing to employ adequate contraception

12. Provide informed written consent

13. Willing to return to enrolling medical site for all study assessments

Registration Exclusion Criteria:

   1. Clinical T4 tumors

   2. Primary surgeon indicates need for abdominoperineal (APR) at baseline

   3. Evidence that the tumor is adherent to or invading the mesorectal fascia on imaging
   studies such that the surgeon would not be able to perform an R0 resection (one with
   negative margins)

   4. Tumor is causing symptomatic bowel obstruction (patients who have had a temporary
   diverting ostomy are eligible).

   5. Chemotherapy within 5 years prior to registration. Hormonal therapy is allowable if
   the disease free interval is ≥ 5 years.

   6. Any prior pelvic radiation

   7. Other invasive malignancy ≤ 5 years prior to registration. Exceptions are colonic
   polyps, non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ,
   or carcinoma-in-situ of the cervix.

   8. Any of the following because this study involves an agent that has known genotoxic,
   mutagenic and teratogenic effects.

      - Pregnant women

      - Nursing women

      - Men or women of childbearing potential who are unwilling to employ adequate

   9. Co-morbid illnesses or other concurrent disease which, in the judgment of the
   clinician obtaining informed consent, would make the patient inappropriate for entry
   into this study or interfere significantly with the proper assessment of safety and
   toxicity of the prescribed regimens.


drug: FOLFOX (chemotherapy)

other: 5 FUCMT (chemoradiation)

procedure: surgery

procedure: magnetic resonance imaging or endorectal ultrasound

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Umara Ahmed

New Trial Alerts

Receive email alerts when trials open to patients.